Company intelligence / Profile preview
Optieum Biotechnologies
Toon City, Ehime Prefecture, Japanoptieumbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Optieum’s lead program OPTF01 targets FAPα in solid tumors and has received significant grant funding to support preclinical development and IND-enabling studies. The company’s Eumbody System platform has demonstrated the ability to generate next-generation CAR-T candidates with improved anti-tumor activity, proliferation capacity, and reduced antigen escape. No clinical results have been published yet as all programs are preclinical.
- Therapeutic areas
- OncologyImmunology
- Modalities
- CAR-T cell therapies (Chimeric Antigen Receptor T-cell)scFv antibody-based therapies (single-chain variable fragment)CAR-NK cell therapies (in partnership context)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
GI CELL (collaboration on NK/CAR-NK technologies)National Cancer Center Japan/NCC-EPOC (joint research on solid tumor immunotherapies)
Beyond the preview
Go deeper on Optieum Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Optieum Biotechnologies.